📰 Tycel Philips News
Tycel Philips News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tycel Philips. Real-time updates on events, politics, business and more.
May 19, 2023
Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.
May 19, 2023
The FDA has approved the first T-cell–engaging bispecific antibody, epcoritamab-bysp (Epkinly), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, after 2 or more lines of systemic therapies.
May 19, 2023
Approval for the T-cell–engaging bispecific antibody came today from the FDA.